SAR 443726
Alternative Names: SAR-443726Latest Information Update: 21 Nov 2022
At a glance
- Originator Sanofi
- Developer Amgen; Sanofi
- Class Monoclonal antibodies; Single-domain antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 13 inhibitors; OX40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis